Objective: To observe the antithrombotic effects of Polygonum amplexicaule decoction and the action of mechanism. Method: After orally given different doses of P. amplexicaule decoction(crude drug dose:0.4

0.2

0.1 g·kg-1) for 7 days

the clotting time of each group mice was determined; thrombus induced by collagen-epinephrine were established

positive control group was orally given 0.5 g·kg-1 Xueshuan Xinmaining tablets

experimental drug group were orally given different doses of P. amplexicaule decoction(crude drug dose:0.6

0.4

0.2 g·kg-1)

model group was given equal volume normal saline once a day for 7 d

then thrombosis-caused hemiplegia and death of each group were determined. Experimental models of artery thrombosis was prepared

they were given P. amplexicaule decoction by intragastric administration for 15 days. Then the blood was taken

the content of plasma thromboxane B2(TXB2)

6-keto-prostaglandin F1α(6-Keto-PGF1α)

tissue-type plasminogen activator(t-PA) and plasminogen activator inhibitor(PAI) were determined. Effect of P. amplexicaule decoction on antiplatelet aggregation induced by ADP

AA and COL were also investigated. Result: The hemostasis time of mice after given high

middle and low doses of P. amplexicaule decoction was (164±23)

(143±20)

(112±21)s

P. amplexicaule decoction could prolong the clotting time of mice; mortality data of thrombotic mice after given high

middle and low doses of P. amplexicaule decoction was 1

2

2

and hemiplegia data of that was 2

2

3

compared with the model group there was significant difference; the content of TXB2

6-Keto-PGF1α

t-PA of blood-stasis model rats could reduce after given P. amplexicaule decoction

content of PAI increased

and inhibite platelet aggregations. Conclusion: P. amplexicaule decoction has obvious antithrombotic effects

which was probably related to platelet functions and aggregations.